07.01.2016 • NewsDede WillamsBrainBiotechnology

Industrial Biotech Firm Brain Plans IPO

In one of the rare stock launches of a German biotechnology company, industrial biotech firm Brain has announced plans to raise a double-digit sum through an initial public offering (ipo) on the Frankfurt stock exchange.

The company based at Zwingenberg near Darmstadt said the money would be spent on commercializing its product pipeline and for research and development as well as financing future acquisitions.

Brain’s CEO, Jürgen Eck, said the planned ipo “will bring the expansion of our company an important step forward.”

Over the past few years, Eck said, the company has “built up an excellent reputation” within the research community, political bodies and the relevant industry players and realized successful collaboration projects.

“We have also made good progress with our industrialization strategy, the CEO added, “thanks to successfully integrated acquisitions and the expansion of our product pipeline. Now we are ready to increase our independence on the financing side, in order to properly benefit from the tailwinds in our industry.”

Brain’s business model is based on the twin pillars of BioScience and BioIndustrial. The first includes R&D collaboration with industrial partners including large industrial players such as BASF, Bayer, Clariant, DSM, Evonik, Fuchs Europe, Henkel, Nutrinova, RWE, Südzucker and Symrise.

The company’s Bioindustrial arm focuses on development and marketing of its own products or active ingredients, in particular enzymes, foodstuffs, wound care biosubstitutes for chemical ingredients. The products are particularly in demand from the cosmetics and personal care sectors.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.